Why is Pep AI making $60K/month?

Is Pep AI really making $60K a month?

Pep AI is clearly operating around the $60K-a-month revenue range, although the public evidence is stronger for monthly revenue than for a clean $60K of recurring MRR.

The best early proof came directly from Pep AI founder Cedric Roberge showing his RevenueCat dashboard during a Starter Story interview. About seven weeks after launch, Pep AI had generated $33,000 during the previous 28 days, reached $51,000 in cumulative revenue and had almost 2,000 active subscriptions. RevenueCat showed roughly $11,000 of MRR at that point.

Growth accelerated after that. In a later Superwall interview, Roberge said Pep AI had gone from about $30,000 of revenue in its first month to $50,000 in its second, with the following month running at an $80,000 pace. He subsequently described the business publicly as a $60K/month app.

Those numbers fit together reasonably well. Pep AI also crossed $100,000 of cumulative revenue in roughly 70 days, so the jump from the original $33,000 monthly run rate clearly happened.

We should therefore use “Pep AI makes around $60K per month” with confidence. Calling it exactly “$60K MRR” goes further than the primary evidence allows.

Pep AI revenue evidence	Figure	What we can conclude
RevenueCat, first ~7 weeks	$33K in previous 28 days	Direct proof of substantial monthly revenue
RevenueCat at the same point	~$11K MRR	Recurring accounting run rate was much lower
RevenueCat at the same point	~2,000 active subscriptions	Pep AI already had a meaningful paying base
Later Superwall interview	$30K → $50K → $80K pace	Monthly revenue kept accelerating
Later founder description	~$60K/month	Reasonable shorthand for the business's scale

Is Pep AI actually at $60K MRR?

Pep AI's public numbers support roughly $60K of monthly sales, while the MRR label remains much less certain.

The difference comes mainly from annual subscriptions. During the first Starter Story breakdown, Pep AI charged about $10 per month or $45 per year. A customer paying $45 upfront creates $45 of immediate cash revenue, but conventional MRR recognizes only $3.75 per month from that subscription.

We can use the early RevenueCat numbers to see how large the effect probably was. With almost 2,000 active subscriptions and around $11,000 of MRR, a simple mix of $10 monthly and $45 annual subscribers would imply roughly 560 monthly subscribers and 1,440 annual subscribers.

That works out to around 72% of subscribers being annual under those simplified assumptions. Discounts, trials and slight differences in the subscriber count mean we should treat the figure as an approximation, but the order of magnitude is useful.

Pep AI's current App Store page makes this distinction even more relevant. It still shows a $9.99 monthly subscription, while several annual offers have existed between roughly $29.99 and $49.99. A $29.99 annual customer adds almost $30 of cash when they subscribe but only around $2.50 to normalized monthly recurring revenue.

So the viral story became slightly cleaner than the accounting underneath it. Pep AI can genuinely collect around $60,000 during a month without having $60,000 of SaaS-style MRR.

What does Pep AI actually help people do?

Pep AI turns a messy peptide or GLP-1 routine into one place where users can keep track of what they are taking, when they took it and what is happening around it.

The current app covers vial inventory, dose logs, reminders, reconstitution calculations, injection sites, weight, side effects, nutrition, hydration, sleep, progress photos, Apple Health data and an educational AI assistant. Recent releases have added things such as a dedicated inventory Vault, rebuilt side-effect tracking, nutrition widgets and dose controls on the iPhone Lock Screen and Dynamic Island.

The original product was far simpler. Roberge launched with the basic ability to add peptides, set reminders and record usage. That was enough because users were already assembling the same workflow themselves.

Starter Story documented one early user who had been managing a protocol through a Google Sheet with 15 tabs. The pattern also appears outside Pep AI. A long-term Shotsy subscriber wrote in an App Store review that she had previously tried notebooks, spreadsheets and even a wall calendar before switching to a dedicated GLP-1 tracker.

Each task is easy on its own. The annoying part starts when someone has to remember schedules, doses, remaining inventory, injection sites, symptoms and progress for weeks or months.

Pep AI packages all of that bookkeeping into one app. The AI features make the product broader today, but the basic reason people open it is still extremely simple: remembering everything manually gets annoying.

Why did peptide and GLP-1 tracking become a real app market so fast?

Pep AI landed in a market where the number of people managing GLP-1 routines was already rising at extraordinary speed.

KFF's latest national polling found that 12% of U.S. adults were currently taking a GLP-1 drug, twice the 6% reported in its May 2024 survey. Around 18% said they had used one at some point.

That is already tens of millions of Americans before we even include the wider peptide audience Pep AI targets.

The money moving through the category has risen just as quickly. IQVIA found that GIP/GLP-1 drugs contributed about $14 billion to the increase in U.S. medicine spending during 2025 alone, with $9.6 billion coming from products used for obesity and related conditions.

Pep AI only needs a tiny fraction of this market. A consumer subscription app doing $60,000 per month at prices around $10 monthly or a few dozen dollars annually can be supported by thousands of paying customers inside an audience measured in the tens of millions.

The opportunity appeared fast because drug adoption moved faster than the software around the behavior. People started managing complicated new routines while the tooling was still mostly generic medication apps, spreadsheets and notes.

Why will people pay $10 a month for Pep AI?

Pep AI can charge around $10 a month because enough users see peptide and GLP-1 tracking as part of an important recurring routine rather than a casual productivity feature.

We already have direct proof of willingness to pay. Pep AI reached almost 2,000 active subscriptions within roughly seven weeks. That happened with the original product, before many of the features available today existed.

The annual pricing makes the decision easier. Pep AI's App Store currently shows yearly offers as low as $29.99. At that price, a year of tracking costs the equivalent of about $2.50 per month.

The app also sits close to something users repeatedly think about. Someone taking a weekly GLP-1 might log the dose, monitor weight, record side effects, check reminders and look at progress. A peptide user managing several compounds can create even more repeated interactions.

Current App Store reviews show both sides of this. Some users explicitly describe the subscription as worth paying for because they rely on the logging and organization. Others complain that core functionality should work better before they pay. That is what we would expect from a real subscription product: the price is acceptable when the tracker becomes part of the routine, while users who never reach that point churn quickly.

The important number is the value of the routine, not the sophistication of the software. Pep AI found a group for whom remembering and organizing this information is worth a few dollars a month.

Did Pep AI simply get lucky by launching early?

Pep AI benefited heavily from timing, but its early validation and speed turned that timing advantage into actual revenue.

The app launched in mid-February 2026 after roughly two weeks of building. Roberge had already found people discussing peptide tracking on Reddit, Instagram and other communities, and Pep AI reportedly had around 300 people waiting before release.

Then the product started converting almost immediately. Starter Story reported around 1,000 users and close to $2,000 of revenue during the first week. Within roughly five weeks, Pep AI reached 10,000 downloads. By its second month, Roberge said the app had 25,000 downloads and had crossed $100,000 of cumulative revenue.

The strongest early experiment came from creators. Roberge described one influencer story generating roughly $1,000. A later feed post from the same relationship reached around 50,000 views and coincided with approximately $4,000 of revenue that day. He estimated that creator eventually generated more than $10,000.

At that point Pep AI had enough evidence to move aggressively. People were downloading the app, some were paying immediately, and niche creators could produce thousands of dollars from individual posts.

The timing gave Pep AI an opening. What happened next came from recognizing that the opening was real and scaling before the category filled with similar apps.

Why did influencer marketing work so well for Pep AI?

Pep AI found a near-perfect match between the product and the people already making peptide and GLP-1 content.

A peptide creator does not need to invent a reason to show the app. Their normal content already covers routines, progress, nutrition, injections, compounds, weight changes and questions from followers. Showing a tracker fits naturally into that conversation.

Roberge spotted another useful gap. During the Superwall interview, he said established GLP-1 tracking apps were heavily focused on paid advertising while peptide creators remained relatively underused as a distribution channel.

Pep AI went aggressively after those creators. By its second month, the company had signed more than 100 fitness influencers, including accounts with audiences above two million followers.

The volume matters here. A normal startup might test five or ten influencers, conclude that results are inconsistent and stop. Pep AI built enough relationships for the randomness of individual posts to matter less.

Some videos failed. Some generated modest traffic. Others produced thousands of dollars. Running the experiment across more than 100 creators gave Pep AI many chances to find the combinations of creator, audience and format that converted.

The app itself also works well visually. A creator can show a schedule, dose history, weight graph or progress screen in seconds. There is very little explanation required before viewers understand what the product does.

What makes Pep AI's creator machine unusually good?

Pep AI turned creator marketing into a high-volume testing operation instead of treating every sponsored post as an isolated campaign.

The scale became surprisingly industrial for such a young app. In the Superwall interview, Roberge described sending more than 1,000 creator outreach messages per week. Trial arrangements could include four videos, four stories and a link in the creator's bio, with a 20% one-time affiliate commission giving creators an additional reason to convert viewers.

That produced a constant stream of content. Pep AI could then compare formats across a much larger sample than a founder producing ads alone.

One result was especially useful: slideshow posts consistently performed better than conventional talking-head UGC across the creator network. Instead of guessing which advertising style people preferred, Pep AI could see the answer emerging from live distribution.

The company also tested whether creators kept generating customers between sponsored posts. Roberge described leaving Pep AI in one creator's bio while asking that creator to publish nothing about the app for two weeks. Downloads still came through the profile.

Some creator relationships were therefore building persistent discovery routes rather than creating one spike on posting day.

This is probably Pep AI's most interesting advantage today. The software can be copied quickly. Building a system that recruits creators every week, tracks their performance, discovers winning creative and keeps producing new experiments takes considerably more work.

Are Meta ads now driving Pep AI's growth?

Meta ads are helping Pep AI scale, but creator marketing was still the main acquisition channel when the founder last disclosed the mix.

Roberge explained the sequence clearly during the Superwall interview. Pep AI first let creators publish organically on TikTok and Instagram. When a piece of content performed well, the company reused the winner as a Meta ad.

Early scripted ads performed poorly. Recycling organic winners worked much better.

The reported cost per download was around $2.50. At the time, Pep AI was spending roughly $400 per day on Meta and another $150 per day on Apple Search Ads. That works out to about $16,500 over a 30-day month if spending remained at the same level.

Roberge was also explicit that influencer marketing was still producing more growth than ads. Meta had become an amplifier for a system that creators were already feeding with tested content.

That is a stronger acquisition setup than relying on paid ads alone. Pep AI gets organic reach from creators, learns which creative works from real audience behavior, and can then buy more impressions behind the winners.

How much does Pep AI's paywall explain the revenue?

Pep AI's paywall is a big reason relatively modest download numbers can turn into tens of thousands of dollars.

The current App Store description says a paid subscription is required to access Pep AI's tracking features. Users encounter a three-day trial and then choose between monthly and annual subscription offers.

The onboarding before that paywall is deliberate. Pep AI asks users about what they want to track and builds context around the product before asking for payment. Roberge has also discussed fixing onboarding mistakes that were suppressing signups before users even reached the subscription screen.

Suppose two apps each get 20,000 downloads. One lets almost everyone use the core product for free and tries to upsell extra features later. The other sends high-intent users through a short trial into a fairly hard subscription decision. Their revenue can end up dramatically different despite identical download counts.

Pep AI has also cycled through multiple annual price points. Apple's current listing contains annual subscription SKUs around $29.99, $39.99, $44.99 and $49.99, alongside the $9.99 monthly option.

That looks like a team actively testing how much friction to remove from the annual decision. At $29.99, the upfront payment is low enough to feel closer to buying an app than committing to an expensive health subscription.

We do not have Pep AI's public trial-to-paid conversion rate, so assigning a precise percentage of the $60,000 to paywall optimization would be guesswork. The mechanism is still visible: targeted traffic arrives with a specific problem, and Pep AI asks for money early.

Does Pep AI's customer-acquisition math really work?

Pep AI's reported $2.50 cost per download leaves plenty of room for a consumer subscription app priced between roughly $30 and $50 per year to work.

Take the cheapest current annual offer, $29.99. Before platform fees and other costs, one annual purchase pays for almost 12 installs acquired at $2.50 each. Pep AI would therefore need roughly 8.3% of those acquired downloads to buy that annual subscription to recover the direct install cost from first-year gross revenue.

At $39.99, the equivalent gross break-even conversion falls to about 6.3%. At $49.99, it is around 5%.

The real calculation is messier. Apple takes a cut, influencer payments add acquisition cost, some users refund or cancel, and monthly subscribers behave differently from annual subscribers. Organic installs also bring the blended acquisition cost down.

Even with those caveats, we do not need heroic assumptions to make the business plausible. Pep AI's pricing is high enough relative to its reported acquisition cost.

Roberge also said the paid campaigns were profitable according to Pep AI's internal conversion data. We cannot independently check that claim because the conversion dashboard is private, but the public numbers pass the basic sanity test.

Annual subscription price	Installs purchasable at $2.50 each	Gross download-to-paid conversion needed to recover ad spend
$29.99	~12	~8.3%
$39.99	~16	~6.3%
$49.99	~20	~5.0%

Is Pep AI still growing quickly today?

Pep AI is still growing and shipping quickly today, even though we cannot verify that its current growth rate matches the extraordinary first few months.

The clearest longer-term signal is downloads. Pep AI had roughly 10,000 downloads after five weeks and 25,000 by its second month. More recently, Roberge announced that the app had passed 100,000 downloads within six months.

Around 75,000 additional downloads therefore arrived after the first 25,000. The initial launch story did not account for most of Pep AI's eventual user base.

The App Store gives us a separate current check. Pep AI now has around 3,500 U.S. ratings, a 4.8 score and sits around #92 in the U.S. Health & Fitness category. Those numbers move over time, but they show an app with meaningful ongoing consumer activity.

Development also remains unusually active. The current version history shows repeated releases across the past few weeks covering side effects, vial inventory, nutrition, reconstitution options, widgets, reminders and dose tracking.

The skeptical version of the story no longer fits very well. Pep AI had a spectacular launch, but the business kept adding users and product depth after the launch window passed.

Are Pep AI's customers likely to keep paying?

Pep AI probably has decent retention because users build up valuable tracking history, although long-term renewal remains the biggest financial unknown in the story.

Over time, Pep AI can accumulate dose history, inventory records, weight changes, side effects, nutrition data, progress photos and other information. Once several months live inside one app, switching becomes more annoying.

The underlying tracking habit can also last a long time. Shotsy, the much larger GLP-1 tracker, currently has around 30,000 U.S. App Store ratings. One recent review came from an annual subscriber who said she had been using the app for almost two years and continued using it after moving into maintenance.

That gives us decent evidence that GLP-1 tracking itself can become a multi-year behavior for some users.

Pep AI still has plenty of ways to lose customers. Current reviews include complaints about data resetting, missing dosing units and the short trial before payment. Health routines also change. Some people stop treatment, simplify their protocols or decide that a spreadsheet is enough.

The main gap is data. Pep AI has publicly shown acquisition, revenue and subscription counts much more openly than cohort retention or annual renewal.

So we can be confident that Pep AI knows how to get paying users. We should be more cautious about how many of today's annual subscribers will still be paying two or three years from now.

Can competitors copy Pep AI easily?

Pep AI's product can be copied quite easily, and current App Store data show that direct competitors are already catching meaningful consumer attention.

The clearest example is PeptidePal. It currently has around 4,300 U.S. App Store ratings, already above Pep AI's roughly 3,500. The app offers peptide and GLP-1 tracking, reconstitution tools, protocol management, injection-site rotation and an educational AI advisor.

Shotsy is even larger on the GLP-1 side, with around 30,000 U.S. ratings and more than one million downloads claimed on its website. It includes dose tracking, reminders, side effects, nutrition, weight and medication-level estimates.

A developer does not need a research breakthrough to reproduce most Pep AI screens. Logs, calculators, reminders, body maps, AI chat and health dashboards are all straightforward features now.

Pep AI's advantage increasingly depends on everything it built around the app: existing users, stored histories, App Store reviews, creator relationships, attribution data, knowledge of which content converts and a team that keeps shipping quickly.

The danger is already visible. PeptidePal's current rating count shows how fast another specialized product can gain ground.

App	Current U.S. App Store ratings	Current positioning	What it tells us
Pep AI	~3.5K	Peptides + GLP-1 tracking	Strong early entrant with a large creator engine
PeptidePal	~4.3K	Peptides + GLP-1 tracking	A direct competitor can scale quickly
Shotsy	~30K	GLP-1 tracking	The broader medication-tracking market is much larger

Could regulation or App Store rules slow Pep AI down?

Pep AI faces a real platform and regulatory risk because part of its growth comes from a health category where the rules around products, claims and advice can tighten quickly.

Apple already created friction during the original launch. Roberge has described having to study how existing health apps framed medical disclaimers before Pep AI could clear review.

The current App Store description is now extremely careful. Pep AI repeatedly presents itself as a tracking and educational tool, says it does not provide medical advice, diagnosis, treatment recommendations or dosing instructions, and tells users to consult healthcare providers for medical decisions.

That wording makes sense given the compounds covered by the app. FDA guidance currently warns that unapproved versions of GLP-1 drugs lack the same premarket review for safety, effectiveness and quality as approved products. The FDA has separately flagged safety concerns or limited safety information around several peptides used in compounding.

Pep AI itself does not have to sell those substances for changes in the surrounding market to affect the business. Tougher restrictions on peptide promotion, tighter app-review standards or stricter rules on AI-generated health information could make acquisition or product development harder.

The same messy market that helped Pep AI find an underserved audience also adds a risk that a normal fitness tracker would face much less often.

So why is Pep AI making $60K a month?

Pep AI is making around $60K a month because it found a fast-growing health behavior with surprisingly bad software, launched before the niche became crowded, and then built an unusually aggressive creator-acquisition machine around it.

The product solved a very concrete annoyance. Peptide and GLP-1 users were already keeping track of schedules, doses, vials, symptoms and progress. Pep AI made that workflow easier without needing users to learn a completely new behavior.

The market underneath it was moving fast enough to do much of the demand creation. KFF's figures show current GLP-1 use doubling from 6% to 12% of U.S. adults in less than two years. Pep AI only needed to convert a tiny corner of that expanding audience.

Then distribution multiplied the opportunity. The company signed more than 100 creators, eventually sent over 1,000 outreach messages per week and learned which content formats converted. Organic winners could be recycled into paid acquisition rather than starting every advertising experiment from scratch.

The monetization was equally aggressive. High-intent users hit a subscription paywall quickly, annual plans collected cash upfront, and the company kept testing onboarding and prices.

Today, the strongest evidence that this was more than a short viral spike is the jump from 25,000 downloads in the second month to more than 100,000 within six months, combined with continued App Store ranking activity and a rapid product-release schedule.

Pep AI's weak point is also much clearer now. Competitors can recreate the software, and PeptidePal has already accumulated more U.S. App Store ratings. Long-term retention is still largely undisclosed.

Our conclusion is pretty sharp: Pep AI reached the $60K/month level because distribution moved much faster than the difficulty of the product would normally justify. The company spotted an exploding niche, shipped a good-enough tracker in weeks, proved that niche creators could sell it, and then scaled that channel harder than the established tracking apps around it.

The AI label helped the pitch. The creator machine made the money.